Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept and Carfilzomib for Lung Transplant AMR and Desensitization
NCT03805178Phase 2Withdrawn
- Sponsor
- Duke University
- Start
- May 2019
- Primary completion
- Aug 2020
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of belatacept in antibody mediated rejection (AMR), transplant sensitization, sponsored by Duke University. Planned start May 2019; status: withdrawn.
02
Drugs
belatacept
03
Conditions
antibody mediated rejection (AMR)transplant sensitization
Beyond the preview
Go deeper on NCT03805178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03805178.